Please login to the form below

Not currently logged in
Email:
Password:

Entereg gets US approval

The US Food and Drug Administration (FDA) has approved Entereg, a medicine manufactured and developed by Adolor and GlaxoSmithKline (GSK).

The US Food and Drug Administration (FDA) has approved Entereg, a medicine manufactured and developed by Adolor and GlaxoSmithKline (GSK).

The medication has been developed to alleviate the symptoms of post-operative ileus (POI). Following extensive studies conducted into the drug's efficacy and safety, the FDA has approved it for use in patients to restore normal gastrointestinal function after undergoing bowel resection surgery. GSK has called Entereg an important new drug for the company that it can now offer to its hospital costumers.

"This approval of Entereg in POI represents a major milestone for Adolor, and is the culmination of a substantial collaborative effort amongst Adolor. GSK and our clinical investigators," said Michael Dougherty, president and chief executive officer of Adolor.

Entereg has been approved with a Risk Evaluation and Mitigation Strategy (REMS) that means limitations have been placed on dispensing of the drug.

Data collected during clinical testing showed that some patients given a twice-daily 0.5mg dose of Entereg experienced myocardial infarction. The FDA has said that it will monitor the product's performance throughout its life cycle.

21st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics